Azenta (AZTA) Expected to Announce Quarterly Earnings on Wednesday

Azenta (NASDAQ:AZTA) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $145.69 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Azenta (NASDAQ:AZTA) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.08. Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%. The business had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $169.66 million. During the same period in the previous year, the company earned $0.13 earnings per share. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, analysts expect Azenta to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Azenta Stock Performance

Azenta stock opened at $52.09 on Tuesday. Azenta has a fifty-two week low of $38.82 and a fifty-two week high of $67.77. The stock has a market cap of $2.38 billion, a PE ratio of -17.54 and a beta of 1.47. The firm’s 50-day simple moving average is $50.09 and its 200 day simple moving average is $49.04.

Insiders Place Their Bets

In other news, CEO John Marotta bought 12,717 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average price of $39.48 per share, with a total value of $502,067.16. Following the acquisition, the chief executive officer now owns 99,612 shares of the company’s stock, valued at approximately $3,932,681.76. The trade was a 14.63 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Herman Cueto sold 712 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $40.07, for a total transaction of $28,529.84. Following the completion of the transaction, the chief financial officer now directly owns 23,892 shares of the company’s stock, valued at approximately $957,352.44. This represents a 2.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,423 shares of company stock valued at $57,020. Company insiders own 10.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Needham & Company LLC cut their price target on shares of Azenta from $69.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Stephens restated an “overweight” rating and set a $60.00 price target on shares of Azenta in a report on Thursday, January 2nd.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.